Great Bay Bio Gained HK SME Innovative Award
Great Bay Bio awarded Merit Award for Innovative Hong Kong SME
[2019/12/18, Hong Kong] On Dec 18th, 2019, Great Bay Bio attends the award ceremony held by Hong Kong Greater China SME Alliance Association, and gained the Merit Award for HK SME Innovative Award. This fully presents the R&D innovative capability of Great Bay Bio, as Great Bay Bio has been continuously enhanced its innovative capability and strived to make global drug development much easier and simpler.
Hong Kong Greater China SME Alliance Association
The Hong Kong Greater China SME Alliance Association anticipates in the promotion of the future economic development of the small and medium enterprises in Hong Kong, in coordinate with the promotion by the Government in the Sino-HK development direction in the Greater Bay Area, actively liaising with the industrial and commercial organizations throughout Mainland China for the purpose of mutual exchange of technologies, providing a wilder vision and developing a co-operation relationship for the creation of collaborative business opportunities. In recent years, there are repeated results by virtue of the promotion in the mutual co-operation amongst the small and medium enterprises and assisting in the career development, to continue to seek more co-operation opportunities by taking advantage of the complimentary resources in both China and Hong Kong and to explore the development ideas between the small and medium enterprises in both China and Hong Kong.
HK SME Innovative Award 2019
The 4th HK SME Innovative Award aims to praise SMEs for their innovative spirit and outstanding performance. To promote the development of Greater Bay Area, the award has allowed all companies in this area to join the contest to facilitate exchanges between Hong Kong and Mainland enterprises, boost their businesses and stimulate their breakthroughs in the future.
About Great Bay Bio
Headquartered in Hong Kong, Great Bay Bio (GBB) is a high-tech enterprise developing biologics with AI technologies. Since its foundation, it has been committed to biotech and biologics development. It has founded Dongguan Taili Biotech Co., Ltd. and Guangzhou Taili Biomedical Technology Co., Ltd. Investing more than RMB 300 million, the company has successfully established the independent and integrated technology platform for drug R&D and large-scale preparation. Through customized CMC packaging services, it has successfully helped several products reach NDA stage, some of which are national class I new drugs.
GBB positions itself as a Contract Development and Manufacturing Organization (CDMO), applying AI technology to CMC (Chemistry, Manufacturing, Control) platform for drug development, which targets the drawbacks of drug development including long timeline and high costs, and solves them with the AI+CMC model. Based on massive datum obtained from conventional biologics development, CMC platform can build models and conduct AI analyses. Integrating AI and biotechnology, it can overcome hurdles in biologics development and greatly reduce the time and costs so as to provide much cheaper, efficient and high-quality drug development service for the clients, and also bring much economical drug to the society.
GBB has been recognized as the Patent Incubation Company, Patent Pilot Company, National High-tech Company, Dongguan New Research Institution, Guangdong Top Ten Foreign R&D Center, Guangdong R&D Center of Genetic Engineering Medicine and Engineering, and Guangdong Doctoral Workstation. Since 2006, it has undertaken a number of government projects. More than RMB 20 million has been received from the government to support its provincial and national projects, such as Guangdong-Hong Kong Key Breakthrough Project and National Major New Drug Projects.
The CMC platform has an area of over 3100 m2 and a whole set of advanced biopharmaceutical R&D equipment. The key equipment has been purchased from world-renowned manufacturers such as Sartorius, Bio-Rad, GE Healthcare, and Waters. The pilot workshop is designed strictly in accordance with cGMP requirements, mainly at the C level and some even at the A level.
For more details, please visit：www.greatbay-bio.com
Contact for business：email@example.com
Contact for media and investment: firstname.lastname@example.org